Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CES2 | O00748 | 3/20 | 0.48 |
| ▸ | THRB | P10828 | 2/20 | 0.48 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.48 |
| ▸ | GMNN | O75496 | 1/20 | 0.48 |
| ▸ | TP53 | P04637 | 1/20 | 0.48 |
| ▸ | POLB | P06746 | 1/20 | 0.48 |
| ▸ | MAPT | P10636 | 1/20 | 0.48 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.48 |
| ▸ | BLM | P54132 | 1/20 | 0.48 |
| ▸ | CA2 | P00918 | 1/20 | 0.46 |
| ▸ | TSHR | P16473 | 3/20 | 0.44 |
| ▸ | FAAH | O00519 | 4/20 | 0.42 |
| ▸ | CES1 | P23141 | 4/20 | 0.42 |
| ▸ | PLA2G6 | O60733 | 1/20 | 0.42 |
| ▸ | PRKD3 | O94806 | 2/20 | 0.38 |
| ▸ | PRKCG | P05129 | 2/20 | 0.38 |
| ▸ | PRKCB | P05771 | 2/20 | 0.38 |
| ▸ | PRKCA | P17252 | 2/20 | 0.38 |
| ▸ | PRKCH | P24723 | 2/20 | 0.38 |
| ▸ | PRKCI | P41743 | 2/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8377211 | 1.00 | CES2 (0.48) | CES2THRBHSD17B10GMNNTP53 | |
| SCHEMBL291759 | 1.00 | CES2 (0.48) | CES2THRBHSD17B10GMNNTP53 | |
| SCHEMBL292460 | 1.00 | CES2 (0.48) | CES2THRBHSD17B10GMNNTP53 | |
| SCHEMBL8378825 | 1.00 | CES2 (0.48) | CES2THRBHSD17B10GMNNTP53 | |
| SCHEMBL204425 | 1.00 | — | — | |
| SCHEMBL201667 | 1.00 | CES2 (0.48) | CES2THRBHSD17B10GMNNTP53 | |
| SCHEMBL8379916 | 1.00 | CES2 (0.48) | CES2THRBHSD17B10GMNNTP53 | |
| SCHEMBL8374782 | 1.00 | CES2 (0.48) | CES2THRBHSD17B10GMNNTP53 | |
| SCHEMBL292062 | 1.00 | CES2 (0.48) | CES2THRBHSD17B10GMNNTP53 | |
| SCHEMBL6063461 | 1.00 | CES2 (0.48) | CES2THRBHSD17B10GMNNTP53 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 34 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2266958-B1 | Antiviral agent | SHIONOGI & CO (JP) | 2017-03-15 | — | — | EP | disclosed |
| US-20170066754-A1 | ANTIVIRAL AGENT | SHIONOGI & CO., LTD. (JP) | 2017-03-09 | — | — | US | disclosed |
| US-9572813-B2 | Antiviral agent | SHIONOGI & CO., LTD. (JP) | 2017-02-21 | — | — | US | disclosed |
| EP-3042894-A1 | ANTIVIRAL AGENT | SHIONOGI & CO., LTD. (JP) | 2016-07-13 | — | — | EP | disclosed |
| US-20150202208-A1 | ANTIVIRAL AGENT | SHIONOGI & CO., LTD. (JP) | 2015-07-23 | — | — | US | disclosed |
| EP-2033952-B1 | Nitrogen-containing Heteroaryl compounds having HIV Integrase Inhibitory Activity | SHIONOGI & CO (JP) | 2012-08-29 | — | — | EP | disclosed |
| EP-1422218-B1 | ANTIVIRAL AGENT | SHIONOGI & CO (JP) | 2012-03-21 | — | — | EP | disclosed |
| EP-2321319-B1 | ANTIVIRAL COMPOUNDS | GILEAD SCIENCES INC (US) | 2012-03-14 | — | — | EP | disclosed |
| US-7998950-B2 | Antiviral compounds | GILEAD SCIENCES, INC. (US) | 2011-08-16 | — | — | US | disclosed |
| EP-2321319-A1 | ANTIVIRAL COMPOUNDS | Gilead Sciences, Inc. (US) | 2011-05-18 | — | — | EP | disclosed |
| EP-1541558-A1 | HETEROCYCLIC COMPOUND HAVING HIV INTEGRASE INHIBITORY ACTIVITY | SHIONOGI & CO., LTD. (JP) | 2005-06-15 | — | — | EP | disclosed |
| US-20040229909-A1 | Antiviral agent | SHIONOGI & CO., LTD. (JP) | 2004-11-18 | — | — | US | disclosed |
| US-20040127708-A1 | Nitrogen-containing heteroaryl compounds having hiv integrase inhibitory activity | SHIONOGI & CO., LTD. (JP) | 2004-07-01 | — | — | US | disclosed |
| EP-1422218-A1 | ANTIVIRAL AGENT | SHIONOGI & CO., LTD. (JP) | 2004-05-26 | — | — | EP | disclosed |
| EP-1375486-A1 | NITROGEN-CONTAINING HETEROARYL COMPOUNDS HAVING HIV INTEGRASE INHIBITORY ACTIVITY | SHIONOGI & CO., LTD. (JP) | 2004-01-02 | — | — | EP | disclosed |
| EP-0751133-B1 | Pyrimidine compound, and liquid crystal composition and liquid crystal element using the same | MITSUI CHEMICALS INC (JP) | 2001-09-12 | — | — | EP | disclosed |
| US-5986042-A | Cross-linked polymer | MITSUI CHEMICALS, INC. (JP) | 1999-11-16 | — | — | US | disclosed |
| EP-0856539-A1 | Cross-linked polymer | Mitsui Chemicals, Inc. (JP) | 1998-08-05 | — | — | EP | disclosed |
| US-5770108-A | HIGH SPEED RESPONSE, MOLECULAR ORIENTATION, HIGH CONTRAST, RECEPTIVITY | MITSUI TOATSU CHEMICALS, INC. (JP) | 1998-06-23 | — | — | US | disclosed |
| EP-0751133-A1 | Pyrimidine compound, and liquid crystal composition and liquid crystal element using the same | MITSUI TOATSU CHEMICALS, INCORPORATED (JP) | 1997-01-02 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040229909-A1 | Antiviral agent | ZC3HAV1, ZC3HAV1L, DUT | CES2 1431/4885THRB 3764/4885HSD17B10 1428/4885 |
| US-20040127708-A1 | Nitrogen-containing heteroaryl compounds having hiv integrase inhibitory activity | DUT, PNP, INMT | CES2 1274/4885THRB 3003/4885HSD17B10 837/4885 |
| US-20150202208-A1 | ANTIVIRAL AGENT | ZC3HAV1, ZC3HAV1L, CCNI | CES2 1872/4885THRB 3798/4885HSD17B10 1765/4885 |
| US-20170066754-A1 | ANTIVIRAL AGENT | ZC3HAV1, ZC3HAV1L, CCNI | CES2 1872/4885THRB 3798/4885HSD17B10 1765/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.